Podchaser Logo
Home
Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival

Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival

Released Monday, 28th September 2009
Good episode? Give it some love!
Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival

Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival

Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival

Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival

Monday, 28th September 2009
Good episode? Give it some love!
Rate Episode

Oncology Times Broadcast News: Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free SurvivalTreatment of advanced pancreatic islet cell tumors with sunitinib has doubled progression-free survival in patients whose options have been very limited up to now, according to French researchers reporting their phase III randomized study findings at the World Congress on Gastrointestinal Cancer in Barcelona (24-27 June, 2009; ABSTRACT: 0-0013). Eric Raymond from Beaujon University Hospital, Villejuif, France, gave Peter Goodwin his clinical interpretation of the findings.

Show More

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features